The present invention concerns the field of heart related disorders in NAFLD patients, and in particular relates to a method of treatment suitable for improving the conditions of heart injury and myocardial related damage in such patients.Cardiovascular diseases (CVD), including coronary heart disease and non-ischemic cardiomyopathy, are the leading cause of death in patients with NAFLD Silibinin administration markedly demonstrated an effectiveness on myocardial damage and an improvement of the myocardiocyte function reversing the accumulation of lipid droplets and consequently improving the condition of these patients.
